Elicera Therapeutics, a company focused on cell and gene therapy, has announced the completion of patient recruitment for its Phase I/II clinical trial of ELC-100. This marks a significant step in the development of ELC-100 as a potential new treatment option. The company anticipates releasing initial results from the first part of the study in the first half of 2025.
Jamal el-Mosleh, CEO of Elicera Therapeutics, stated that ELC-100 "stands apart from all other standard treatments." This highlights the company's belief in the unique mechanism and potential benefits of their cell and gene therapy approach.
The Phase I/II study is designed to evaluate the safety and efficacy of ELC-100 in patients with specific cancer types. The trial's completion of patient recruitment allows for focused data collection and analysis, bringing the company closer to understanding the therapeutic potential of ELC-100.
Further details about the specific cancer types targeted, dosing regimens, and trial endpoints were not disclosed in the provided source. However, the completion of patient recruitment represents a critical milestone for Elicera Therapeutics and the advancement of ELC-100.
